Latest news with #TriClip
Malaysian Reserve
4 days ago
- Business
- Malaysian Reserve
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ — The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. 'This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease,' says Dr. Shavelle, who led the landmark procedure. 'Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life.' This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. 'The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day,' says Dr. Shavelle. 'It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being.' The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as 'Best Hospital' for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit
Yahoo
4 days ago
- Business
- Yahoo
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ -- The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. "This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease," says Dr. Shavelle, who led the landmark procedure. "Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life." This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. "The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day," says Dr. Shavelle. "It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being." The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as "Best Hospital" for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit View original content to download multimedia: SOURCE MemorialCare Long Beach Medical Center
Yahoo
29-05-2025
- Business
- Yahoo
Abbott Stock Gains Following FDA Approval of the Tendyne System
Abbott Laboratories ABT has recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement ('TMVR') system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification ('MAC'). The Tendyne system expands the company's comprehensive Structural Heart portfolio. After the announcement, Abbott shares edged up 1.3%, finishing at $132.94 yesterday. The company's Structural Heart arm benefits from a unique range of product portfolio, which includes MitraClip, a mitral valve transcatheter edge-to-edge repair system, and TriClip, a tricuspid valve transcatheter edge-to-edge repair system. The portfolio also contains transcatheter aortic heart valves — Portico and Navitor. Hence, we expect the market sentiment toward ABT stock to remain positive surrounding the latest development. Abbott holds a market capitalization of $231.29 billion. The company's earnings yield of 3.9% surpasses the industry's 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters. MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Image Source: Zacks Investment Research Per Medi-Tech Insights' report, the TMVR market is projected to witness a compound annual growth rate of 20% from 2025 to 2030. Key factors driving growth are increased prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population. Earlier this month, Abbott unveiled results from its REFLECT real-world studies, conducted using data from the comprehensive Swedish National Diabetes Register. The findings revealed that the company's FreeStyle Libre continuous glucose monitoring (CGM) technology helps significantly reduce the risk of hospitalization for heart complications in people with diabetes. Over the past year, Abbott's shares have risen 32%, surpassing the industry's 10.3% growth. Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, AngioDynamics ANGO and STERIS STE. PAHC carries a Zacks Rank #1 (Strong Buy) at present. It has an estimated long-term earnings growth rate of 26.2% compared with the industry's 15.9%. You can see the complete list of today's Zacks #1 Rank stocks here. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 30.6%. Its shares have rallied 26.3% compared with the industry's 10% growth in the past year. AngioDynamics, carrying a Zacks Rank #1 at present, has an estimated earnings growth rate of 23.7% for 2025. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. ANGO's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Abbott Stock Gains Following FDA Approval of the Tendyne System
Abbott Laboratories ABT has recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement ('TMVR') system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification ('MAC'). The Tendyne system expands the company's comprehensive Structural Heart portfolio. After the announcement, Abbott shares edged up 1.3%, finishing at $132.94 yesterday. The company's Structural Heart arm benefits from a unique range of product portfolio, which includes MitraClip, a mitral valve transcatheter edge-to-edge repair system, and TriClip, a tricuspid valve transcatheter edge-to-edge repair system. The portfolio also contains transcatheter aortic heart valves — Portico and Navitor. Hence, we expect the market sentiment toward ABT stock to remain positive surrounding the latest development. Abbott holds a market capitalization of $231.29 billion. The company's earnings yield of 3.9% surpasses the industry's 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters. MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Image Source: Zacks Investment Research Per Medi-Tech Insights' report, the TMVR market is projected to witness a compound annual growth rate of 20% from 2025 to 2030. Key factors driving growth are increased prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population. Earlier this month, Abbott unveiled results from its REFLECT real-world studies, conducted using data from the comprehensive Swedish National Diabetes Register. The findings revealed that the company's FreeStyle Libre continuous glucose monitoring (CGM) technology helps significantly reduce the risk of hospitalization for heart complications in people with diabetes. Over the past year, Abbott's shares have risen 32%, surpassing the industry's 10.3% growth. Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, AngioDynamics ANGO and STERIS STE. PAHC carries a Zacks Rank #1 (Strong Buy) at present. It has an estimated long-term earnings growth rate of 26.2% compared with the industry's 15.9%. You can see the complete list of today's Zacks #1 Rank stocks here. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 30.6%. Its shares have rallied 26.3% compared with the industry's 10% growth in the past year. AngioDynamics, carrying a Zacks Rank #1 at present, has an estimated earnings growth rate of 23.7% for 2025. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. ANGO's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty
Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 testing-related sales. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09. 'Once again, Abbott's diversified business model delivered top-tier sales and EPS growth,' said Robert Ford, chairman and CEO of Abbott. 'It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.' Also Read: Medical Device sales increased 9.9% to $4.89 billion with organic growth of 12.6%, led by Diabetes Care, Structural Heart, Heart Failure and Electrophysiology. Several products, including FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet, and AVEIR, contributed to the strong performance. In Diabetes Care, sales of continuous glucose monitors were $1.7 billion and grew 18.3% on a reported basis and 21.6% on an organic basis. Nutrition sales of $2.15 billion increased 3.8% on a reported basis and 6.8% on an organic basis in the first quarter. In Pediatric Nutrition, global sales increased 3.2% on a reported basis and 4.9% on an organic basis. In Adult Nutrition, global sales of $1.11 billion increased 4.4% on a reported basis and 8.7% on an organic basis, which was led by strong growth of Ensure and Glucerna. Global Diagnostics sales of $2.05 billion decreased 7.2% on a reported basis, down 4.9% on an organic basis, or increased 0.5% when excluding COVID-19 testing-related sales. The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth. COVID-19 testing-related sales were $84 million in the quarter, compared to $204 million a year ago. Global Core Laboratory Diagnostics sales decreased 2.3% on a reported basis and increased 0.9% on an organic basis. Abbott's reported operating margin was 16.3% of sales, and adjusted operating margin of 21%, which reflects a 130 basis point increase year-over-year. Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%. Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25. In March, Abbott received European approval for the Volt PFA System for atrial fibrillation (AFib). The company will further expand its use in EU markets throughout the second half of the year. Last month, Abbott also announced late-breaking data from its TRILUMINATE trial that show the TriClip transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. Price Action: ABT stock is up 5.02% at $132.55 at the last check on Wednesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
